Acute lung injury (ALI) most commonly occurs after severe bacterial infections such as pneumonia or sepsis. A clear impediment to successful ALI therapy resides in a complex disease course often characterized by an initial burst in host inflammation from pro- inflammatory mediators resulting in extensive tissue injury;a second phase of immunosuppression ensues that poses risks for secondary bacterial infections. IL-1, generated by the inflammasome and invasive bacterial infections both contribute to disease pathobiology and illness severity. The mechanistic platform of this project resides on our discovery of a unique molecular model of inflammation whereby a relatively new protein, Fbxo3, potently triggers IL-1 release from human inflammatory cells after bacterial infection by destabilizing a crucial inflammasome inhibitor, Fbxl2. By targeting the ApaG molecular signature present in both host Fbxo3 and many bacteria, we developed a first-in-class genus of small molecule inhibitors that display dual anti-inflammatory and anti-bacterial activity in murine ALI models. Hence, in this application we will first elucidate how bacterial pathogens transcriptionally activate Fbxo3, allowing the protein to eliminate an inflammasome inhibitor, Fbxl2 (Aim 1). We will specifically elucidate how Fbxl2 targets the NALP7 inflammasome. Next we will optimize the pharmacologic design and test a novel small molecule that exhibits distinct, and yet complementary anti-inflammatory and anti-bacterial properties in ALI models (Aim 2). These studies will provide a new mechanistic pathway of innate immunity that will serve as a basis to fulfill an unmet therapeutic need in subjects with altered immune responses during critical illness.
Acute lung injury (ALI) is a major cause of morbidity and mortality in the US and evidence suggests that patients die from overwhelming inflammation or immunosuppression, the latter making people prone to bacterial infections. Lung inflammation is caused from the release of proteins, called cytokines. We have discovered a new model of inflammation in subjects with ALI. This discovery led us to develop a new family of drugs that reduce cytokine-driven inflammation but are also anti- bacterial. This discovery fulfills an unmet need in ALI therapy.
|Zou, Chunbin; Synan, Matthew J; Li, Jin et al. (2016) LPS impairs oxygen utilization in epithelia by triggering degradation of the mitochondrial enzyme Alcat1. J Cell Sci 129:51-64|
|Krzysiak, Troy C; Chen, Bill B; Lear, Travis et al. (2016) Crystal structure and interaction studies of the human FBxo3 ApaG domain. FEBS J 283:2091-101|
|Liu, Yuan; Mallampalli, Rama K (2016) Small molecule therapeutics targeting F-box proteins in cancer. Semin Cancer Biol 36:105-19|
|Agassandian, Marianna; Tedrow, John R; Sembrat, John et al. (2015) VCAM-1 is a TGF-Î²1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal 27:2467-73|
|Han, SeungHye; Lear, Travis B; Jerome, Jacob A et al. (2015) Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting Its Ubiquitination and Degradation Mediated by the SCFFBXL2 E3 Ligase. J Biol Chem 290:18124-33|
|Londino, James D; Gulick, Dexter; Isenberg, Jeffrey S et al. (2015) Cleavage of Signal Regulatory Protein Î± (SIRPÎ±) Enhances Inflammatory Signaling. J Biol Chem 290:31113-25|
|Chen, Wei; Xiong, Sheng; Li, Jin et al. (2015) The ubiquitin E3 ligase SCF-FBXO24 recognizes deacetylated nucleoside diphosphate kinase A to enhance its degradation. Mol Cell Biol 35:1001-13|
|Liu, Yuan; Lear, Travis; Iannone, Olivia et al. (2015) The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by Mediating the Ubiquitylation and Proteasomal Degradation of Survivin. J Biol Chem 290:11843-52|
|Liu, Y; Lear, T; Zhao, Y et al. (2015) F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7. Cell Death Dis 6:e1630|
|Han, SeungHye; Mallampalli, Rama K (2015) The acute respiratory distress syndrome: from mechanism to translation. J Immunol 194:855-60|
Showing the most recent 10 out of 35 publications